Privately-owned central nervous system specialist Neuraxpharm has struck a deal with Sanofi to acquire two product portfolios for CNS, pain and vascular diseases, a move which it expects will lead to its annual gross sales hitting around €600m ($603m) and will significantly expand its portfolio of branded products.
Neuraxpharm says the move will “strengthen its position as a leading European specialty pharmaceutical company focused on CNS